| Program | Target | Format | Discovery | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|
| POB-1032 | MC4R | Peptide | |||||
| POB-016 | GLP-1/GIP | Biologic | |||||
| POB-027 | FGF21 | Biologic | |||||
| POB-1374 | FGF21; GLP-1 | Fusion Protein | |||||
| POB-062 | β2AR | To be disclosed | |||||
| POB-048 | ACVR2 | Biologic | |||||
| POB-0526 | GOAT | Small Molecule | |||||
| POB-0119 | GDF15 | Biologic | |||||
| POB-022 | To be disclosed | To be disclosed | |||||
| POB-079 | To be disclosed | To be disclosed | |||||
Let's Advance Obesity Research Together
We welcome scientists, researchers, and industry partners worldwide to collaborate on innovative research projects and accelerate the development of next-generation therapies.
Why Partner With Us
Integrated Expertise
End-to-end capabilities from target discovery to translational validation.
Advanced Platforms
State-of-the-art technologies and disease models to drive high-impact research.
Global Collaboration
Work with leading scientists and partners across the world.
Quality & Compliance
Committed to rigorous quality standards and regulatory excellence.
If you are interested in collaborating or have a project in mind,
we'd love to hear from you.
Let’s discuss how we can work together to drive meaningful breakthroughs.
Therapy Development
We advance the development of innovative anti-obesity therapies through comprehensive target validation, mechanism-of-action studies, efficacy evaluation, and translational research, supporting next-generation treatments for obesity and metabolic disorders.
Preclinical Studies
Our extensive library of validated obesity and metabolic disease models enables comprehensive evaluation of the efficacy, safety, pharmacodynamics, and mechanisms of novel anti-obesity therapeutics, accelerating preclinical development and translational research.
Pioneering a New Chapter in Obesity Treatment: Collaboration Opportunities
Protheragen is at the forefront of innovation in obesity therapy, targeting key biomarkers, and has established a scientifically rigorous pipeline for the development of anti-obesity drugs. We are committed to addressing the future challenges of obesity treatment and invite biotechnology innovators, pharmaceutical industry leaders, and digital health pioneers to explore potential collaboration opportunities and research obesity treatment together. If you are interested, please do not hesitate to contact us to learn more about our cutting-edge research in obesity treatment.